DENVER, Nov. 28, 2005 (PRIMEZONE) -- Chelsea Management Group Inc. (Other OTC:CLMP) has successfully completed an agreement to market, distribute and promote Anxius(tm), a revolutionary natural antidepressant alternative to drugs like Prozac, Paxil, and Zoloft, which fall under the acronym SSRI. Recently SSRI prescriptions have generated a lot of controversy, namely the side effects associated with SSRIs have been put under the spotlight.
Anxius(tm) is a herbal supplement that works to supply your brain with the repair tools needed to bring your neurotransmitter levels back to a healthy balance. The working ingredients in Anxius(tm) will provide the exact nutrient supplements that your brain requires to be able to correct itself within days and even hours. Anxius(tm) has been designed to be safe enough to take on a permanent basis, yet potent enough to not only treat, but prevent you from relapsing into depression, anxiety and chronic stress in the future.
There are more than 45 million people taking antidepressant drugs, or SSRIs, and millions more are considering using them. Anxius(tm) is a natural herbal supplement, affordably priced and available without prescription. An overwhelming 90% have reported major improvements in their depression, anxiety and overall mood disorders within days, some within 24 hours of treatment by using Anxius(tm) supplements, according to the company.
The company will be forming a series of cyber distribution outlets and direct marketing programs under Chelsea's Life Sciences Wellness Center division. "It is our intention to get the product as efficiently and quickly to the marketplace without sacrificing quality of service and profitability," said Peter Johansen, CEO of Chelsea. A distribution and marketing plan is being put in place and new developments will be announced as they occur.
Chelsea Management Group is a start-up and early-stage venture capital firm focused on the health and life sciences industry. Formed in 2001, Chelsea searches for the winners of tomorrow -- entrepreneurs whose ideas and talents qualify them to pursue large market opportunities successfully. We seek opportunities across a broad spectrum, including biotechnology and pharmaceuticals, medical devices, services and healthcare/life sciences information technology. On a selective basis, we also consider later-stage health and life sciences investments where we can uniquely apply Chelsea's industry and capital markets experience.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e. future operational results and sales) are subject to assumptions and beliefs based on current information known to the company and factors that are subject to uncertainties, risk and other influences, which are outside the company's control and may yield results differing materially from those anticipated.